secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001654954-25-012921
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics Q3 net loss $15.8M; Phase 3 LEVEL enrollment on track
------------------------------------------------------------------------

- Net loss of $15.8M for Q3 2025 vs $4.0M in Q3 2024; R&D expenses $10.3M (up from $3.1M).
- Cash and cash equivalents $99.4M as of Sept 30, 2025; expected to fund operations through 2027.
- Phase 3 LEVEL study (TNX-103) targeting 230 patients; enrollment completion expected H1 2026, topline data H2 2026.
- On track to initiate second Phase 3 study LEVEL-2 in 2025; 160+ global sites qualified.
- European Patent Office intends to grant patent for levosimendan in PH-HFpEF, extending IP to Dec 2040.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495425012921/0001654954-25-012921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495425012921/tennx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-012921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer